Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 12, 2008, Pages 3616-3621

  Ruebsam, Frank ^a   Webber, Stephen E ^a   Tran, Martin T ^a   Tran, Chinh V ^a   Murphy, Douglas E ^a   Zhao, Jingjing ^a   Dragovich, Peter S ^a   Kim, Sun Hee ^a   Li, Lian Sheng ^a   Zhou, Yuefen ^a   Han, Qing ^a   Kissinger, Charles R ^a   Showalter, Richard E ^a   Lardy, Matthew ^a   Shah, Amit M ^a   Tsan, Mei ^a   Patel, Rupal ^a   LeBrun, Laurie A ^a   Kamran, Ruhi ^a   Sergeeva, Maria V ^a   Bartkowski, Darian M ^a   Nolan, Thomas G ^a   Norris, Daniel A ^a   Kirkovsky, Leo ^a   more..

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Hepatitis C virus (HCV); Non nucleoside NS5B inhibitor; NS5B polymerase; Pyrrolo 1,2 b pyridazin 2 one; Small molecule; Structure based design

Indexed keywords

DNA DIRECTED DNA POLYMERASE ALPHA; ENZYME INHIBITOR; PYRROLO[1,2 B]PYRIDAZIN 2 ONE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIPOPHILICITY; LIVER MICROSOME; NONHUMAN; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BINDING SITES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROGEN BONDING; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRIDAZINES; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 44649152230     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.04.066     Document Type: Article

References (39)

1. Kim W.R. Hepatology 36 (2002) 30
2. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., Kaslow R.A., and Margolis H.S. N. Engl. J. Med. 341 (1999) 556
3. Alberti A., and Benvegnu L. J. Hepatol. 38 (2003) S104
4. Sidwell R.W., Huffman J.H., Khare G.P., Allen L.B., Witkowski J.T., and Robins R.K. Science 177 (1972) 705
5. Smith R.A., and Kirkpatrick W. Ribavirin, a Broad Spectrum Antiviral Agent Vol. xiii (1980), Academic Press, New York 237
6. De Clercq E. Adv. Virus Res. 42 (1993) 1
7. Hoofnagle J.H., and Seeff L.B. N. Eng. J. Med. 355 (2007) 2444
8. Kolykhalov A.A., Agapov E.V., Blight K.J., Mihalik K., Feinstone S.M., and Rice C.M. Science 277 (1997) 570
9. Koch U., and Narjes F. Curr. Top. Med. Chem. 7 (2007) 1302
10. Slater M.J., Amphlett E.M., Andrews D.M., Bravi G., Burton G., Cheasty A.G., Corfield J.A., Ellis M.R., Fenwick R.H., Fernandes S., Guidetti R., Haigh D., Hartley C.D., Howes P.D., Jackson D.L., Jarvest R.L., Lovegrove V.L.H., Medhurst K.J., Parry N.R., Price H., Shah P., Singh O.M.P., Stocker R., Thommes P., Wilkinson C., and Wonacott A. J. Med. Chem. 50 (2007) 897
11. Dhanak D., Duffy K.J., Johnston V.K., Lin-Goerke J., Darcy M., Shaw A.N., Gu B., Silverman C., Gates A.T., Nonnemacher M.R., Earnshaw D.L., Casper D.J., Kaura A., Baker A., Greenwood C., Gutshall L.L., Maley D., DelVecchio A., Macarron R., Hofmann G.A., Alnoah Z., Cheng H.-Y., Chan G., Khandekar S., Keenan R.M., and Sarisky R.T. J. Biol. Chem. 277 (2002) 38322
12. Evans K.A., Chai D., Graybill T.L., Burton G., Sarisky R.T., Lin-Goerke J., Johnston V.K., and Rivero R.A. Bioorg. Med. Chem. Lett. 16 (2006) 2205
13. Blake, J. F.; Fell, J. B.; Fischer, J. P.; Hendricks, R. T.; Spencer, S. R.; Stengel, P. J. WO2006117306, 2006.
14. Pratt J.K., Donner P., McDaniel K.F., Maring C.J., Kati W.M., Mo H., Middleton T., Liu Y., Ng T., Xie Q., Zhang R., Montgomery D., Molla A., Kempf D.J., and Kohlbrenner W. Bioorg. Med. Chem. Lett. 15 (2005) 1577
15. Hutchinson, D. K. et al. U.S. Patent US2005107364, 2005.
16. All structures are arbitrarily drawn as one of several possible tautomers.
17. Tedesco R., Shaw A.N., Bambal R., Chai D., Concha N.O., Darcy M.G., Dhanak D., Fitch D.M., Gates A., Gerhardt W.G., Halegoua D.L., Han C., Hofmann G.A., Johnston V.K., Kaura A.C., Liu N., Keenan R.M., Goerke J.L., Sarisky R.T., Wiggall K.J., Zimmerman M.N., and Duffy K.J. J. Med. Chem. 49 (2006) 971
18. Zhou Y., Webber S.E., Murphy D.E., Li L.-S., Dragovich P.S., Tran C.V., Sun Z., Ruebsam F., Shah A., Tsan M., Showalter R., Patel R., Li B., Zhao Q., Han Q., Hermann T., Kissinger C., LeBrun L., Sergeeva M.V., and Kirkovsky L. Bioorg. Med. Chem. Lett. 18 (2008) 1413
19. Zhou Y., Li L.-S., Dragovich P.S., Murphy D.E., Tran C.V., Ruebsam F., Webber S.E., Shah A., Tsan M., Averill A., Showalter R., Patel R., Han Q., Zhao Q., Hermann T., Kissinger C., LeBrun L., and Sergeeva M.V. Bioorg. Med. Chem. Lett. 18 (2008) 1419
20. Li, L.-S.; Zhou, Y.; Murphy, D. E.; Stankovic, N.; Zhao, J.; Dragovich, P. S.; Bertolini, T.; Sun, Z.; Ayida, B.; Tran, C. V.; Ruebsam, F.; Webber, S. E.; Shah, A. M.; Tsan, M.; Showalter, R. E.; Patel, R.; LeBrun, L. A.; Bartkowski, D. M.; Nolan, T. G.; Norris, D. A.; Kamran, R.; Brooks, J.; Sergeeva, M. V.; Kirkovsky, L.; Zhao, Q.; Kissinger, C. R. Bioorg. Med. Chem. Lett. 2008. Available from doi:10.1016/j.bmcl.2008.02.072.
21. Sergeeva M.V., Zhou Y., Bartkowski D.M., Nolan T.G., Norris D.A., Okamoto E., Kirkovsky L., Kamran R., LeBrun L.A., Tsan M., Patel R., Shah A.M., Lardy M., Gobbi A., Li L.-S., Zhao J., Bertolini T., Stankovic N., Sun Z., Murphy D.E., Webber S.E., and Dragovich P.S. Bioorg. Med. Chem. Lett. 18 (2008) 3421
22. Veber D.F., Johnson S.R., Cheng H.-Y., Smith B.R., Ward K.W., and Kopple K.D. J. Med. Chem. 45 (2002) 2615
23. Palm K., Stenberg P., Luthman K., and Artursson P. Pharm. Res. 14 (1997) 568
24. 2 at pH 7.6 and an inhibitor concentration of 2-10 mM. Diffraction data were collected to a resolution of 2.1 Å for compound 3c. The crystal structure discussed in this paper has been deposited in the Protein Databank (www.rcsb.org) with entry code: 3CO9. Full structure determination details are provided in the PDB entry.
25. Ruebsam, F.; Tran, M. T.; Webber, S. E.; Dragovich, P. S.; Li, L.-S.; Murphy, D. E.; Kucera, D. J.; Sun, Z.; Tran, C. V. PCT International Patent Application, WO 2007150001 A1, 2007.
26. Intermediate 7a was prepared using modified literature procedures as described in. Krueger A.C., Madigan D.L., Green B.E., Hutchinson D.K., Jiang W.W., Kati W.M., Liu Y., Maring C.J., Masse S.V., McDaniel K.F., Middleton T.R., Mo H., Molla A., Montgomery D.A., Ng T.I., and Kempf D. J. Bioorg. Med. Chem. Lett. 17 (2007) 2289
27. Hutchinson, D. K. et al. United States Patent Application #: 2005/0107364.
28. Goldfarb A.R., and Berk B. J. Am. Chem. Soc. 65 (1943) 738
29. intermediate 7b was prepared using modified literature procedures as described in. Fitch M.D., Evans K.A., Chai D., and Duffy K.J. Org. Lett. 7 (2005) 5521
30. Kovalenko S.N., Chernykh V.P., Shkarlat A.E., Ukrainets I.V., Gridasov V.I., and Rudnev S.A. Chem. Heterocycl. Compd. (Engl. Transl.) 34 (1999) 791
31. Intermediate 7c was prepared as described in Dragovich, P. S.; Murphy, D. E.; Tran, C. V.; Ruebsam, F. Synth. Commun. 2008. Available from doi:10.1080/00397910801997512.
32. Deng W., Liu L., Zhang C., Liu M., and Guo Q.-X. Tetrahedron Lett. 46 (2005) 7295
33. Waldmann H., and Kunz H. Liebigs Ann. Chem. (1983) 1712
34. Friedrich-Bochnitschek S., Waldmann H., and Kunz H. J. Org. Chem. 54 (1989) 751
35. Demange L., Menez A., and Dugave C. Tetrahedron Lett. 39 (1998) 1169
36. Leroy J., Porhiel E., and Bondon A. Tetrahedron 58 (2002) 6713
37. Loader C.E., and Anderson H.J. Can. J. Chem. 59 (1981) 2673
38. Bhattacharya A., Patel N.C., Plata R.E., Peddicord M., Ye Q., Parlanti L., Palaniswamy V.A., and Grosso J.A. Tetrahedron Lett. 47 (2006) 5341
39. Hynes J., Doubleday W.W., Dyckman A.J., Godfrey J.D., Grosso J.A., Kiau S., and Leftheris K. J. Org. Chem. 69 (2004) 1368